Last reviewed · How we verify
SHR-1316; Carboplatin; Etoposide；Radiotherapy
SHR-1316; Carboplatin; Etoposide；Radiotherapy is a Platinum-based chemotherapy Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell growth and inducing apoptosis.
Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting cancer cell growth and inducing apoptosis. Used for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | SHR-1316; Carboplatin; Etoposide；Radiotherapy |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Etoposide is a topoisomerase inhibitor that works by stabilizing the cleavage complex of DNA, thereby preventing DNA replication and transcription. Radiotherapy is a form of cancer treatment that uses high-energy radiation to kill cancer cells.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
- Ovarian cancer
- Testicular cancer
- Other cancers
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer (PHASE2)
- SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC (PHASE2)
- A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma (PHASE2)
- A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (PHASE2)
- The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1316; Carboplatin; Etoposide；Radiotherapy CI brief — competitive landscape report
- SHR-1316; Carboplatin; Etoposide；Radiotherapy updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about SHR-1316; Carboplatin; Etoposide；Radiotherapy
What is SHR-1316; Carboplatin; Etoposide；Radiotherapy?
How does SHR-1316; Carboplatin; Etoposide；Radiotherapy work?
What is SHR-1316; Carboplatin; Etoposide；Radiotherapy used for?
Who makes SHR-1316; Carboplatin; Etoposide；Radiotherapy?
What drug class is SHR-1316; Carboplatin; Etoposide；Radiotherapy in?
What development phase is SHR-1316; Carboplatin; Etoposide；Radiotherapy in?
What are the side effects of SHR-1316; Carboplatin; Etoposide；Radiotherapy?
Related
- Drug class: All Platinum-based chemotherapy drugs
- Manufacturer: Jiangsu HengRui Medicine Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Ovarian cancer